Solaris Pharma Corporation is currently developing several topical & transdermal products, which are in different stages of development. The company has a dedicated team of committed and well-trained scientists along with experienced program managers and regulatory personnel who provide a robust product development process. The entire end-to-end product development process has been validated through multiple product approvals. A robust commercial infrastructure is in place to market our approved products. The commercial team has reinforced our success with product approvals in successfully launching our first product under the Solaris label into the market.
The topical dosage forms that are being developed at our facility include: Ointments, Gels, Creams, Lotions, Solutions, Sprays, and Foams.
These products target several indications such as: Pain, Acne, Psoriasis, Atopic Dermatitis, Fungal infections, and Rosacea